TY - JOUR
T1 - Design of the Texas Hepatocellular Carcinoma Consortium Cohort Study
AU - Feng, Ziding
AU - Marrero, Jorge A.
AU - Khaderi, Saira
AU - Singal, Amit G.
AU - Kanwal, Fasiha
AU - Loo, Nicole
AU - Beretta, Laura
AU - Ning, Jing
AU - El-Serag, Hashem B.
N1 - Funding Information:
Cancer Prevention & Research Institute of Texas grant (RP150587). The works is also supported in part by the Center for Gastrointestinal Development, Infection and Injury (NIDDK P30 DK 56338).
Publisher Copyright:
© 2018 by The American College of Gastroenterology.
PY - 2019/3/1
Y1 - 2019/3/1
N2 - OBJECTIVES:The Texas Hepatocellular Carcinoma Consortium cohort study investigates risk factors of hepatocellular carcinoma (HCC) and biomarkers for early HCC detection in patients with liver cirrhosis.METHODS:Adult patients with liver cirrhosis are enrolled at 5 clinical centers from 3 cities in Texas, with a target of 5,000 patients. Clinical history, risk factor questionnaires, liver imaging, laboratory data, and blood samples were collected at enrollment and at each 6-month follow-up visit.RESULTS:The primary outcome was the development of HCC. Biomarkers were tested in banked blood samples using prospective specimen collection, retrospective blinded evaluation design.CONCLUSIONS:We describe study design, eligibility criteria, recruitment, study cores, and sample size and analysis considerations.
AB - OBJECTIVES:The Texas Hepatocellular Carcinoma Consortium cohort study investigates risk factors of hepatocellular carcinoma (HCC) and biomarkers for early HCC detection in patients with liver cirrhosis.METHODS:Adult patients with liver cirrhosis are enrolled at 5 clinical centers from 3 cities in Texas, with a target of 5,000 patients. Clinical history, risk factor questionnaires, liver imaging, laboratory data, and blood samples were collected at enrollment and at each 6-month follow-up visit.RESULTS:The primary outcome was the development of HCC. Biomarkers were tested in banked blood samples using prospective specimen collection, retrospective blinded evaluation design.CONCLUSIONS:We describe study design, eligibility criteria, recruitment, study cores, and sample size and analysis considerations.
UR - http://www.scopus.com/inward/record.url?scp=85062598631&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85062598631&partnerID=8YFLogxK
U2 - 10.14309/ajg.0000000000000068
DO - 10.14309/ajg.0000000000000068
M3 - Article
C2 - 30699099
AN - SCOPUS:85062598631
SN - 0002-9270
VL - 114
SP - 530
EP - 532
JO - American Journal of Gastroenterology
JF - American Journal of Gastroenterology
IS - 3
ER -